Novartis Feed

2026-01-16 18:00:00 Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease

2026-01-09 16:30:00 Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment 113,82 CHF | +0,04%

2025-12-19 20:30:21 Novartis and US government reach agreement on lowering drug prices in the US

2025-12-12 13:00:00 Novartis breaks ground on flagship manufacturing hub in North Carolina 105,31 CHF | -0,69%

2025-12-09 13:30:00 Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses 106,86 CHF | +0,26%

2025-12-09 13:15:00 1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years 106,86 CHF | +0,26%

2025-11-25 07:15:00 Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS 104,83 CHF | +1,38%

2025-11-24 23:16:48 Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA) 104,83 CHF | +1,38%

2025-11-20 07:00:00 Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets 100,30 CHF | -1,91%

2025-11-19 18:30:00 Novartis announces plans to build flagship manufacturing hub in North Carolina 100,30 CHF | -1,91%

2025-11-12 23:00:00 Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance 105,92 CHF | +1,08%

2025-11-10 15:30:00 Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan 102,20 CHF | +0,33%

2025-11-04 07:15:00 New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline 101,30 CHF | +1,59%

2025-10-29 15:30:00 Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials 98,02 CHF | -0,68%

2025-10-28 14:52:48 Novartis completes acquisition of Tourmaline Bio 98,69 CHF | -4,29%

2025-10-28 07:25:00 Novartis announces expiration of Tourmaline Bio tender offer 98,69 CHF | -4,29%

2025-10-28 07:00:00 Novartis verzeichnet im dritten Quartal solide Steigerungen beim Umsatz und operativen Kernergebnis sowie starke Fortschritte in der Pipeline; Prognose für das Geschäftsjahr 2025 bestätigt 98,69 CHF | -4,29%

2025-10-28 07:00:00 Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance 98,69 CHF | -4,29%

2025-10-26 18:00:00 Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline 103,11 CHF | -1,07%

2025-10-25 17:00:00 Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases

2025-10-22 07:15:00 Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR) 105,25 CHF | +0,62%

2025-10-22 07:00:00 Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer 105,25 CHF | +0,62%

2025-10-19 16:30:00 PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer

2025-10-17 14:00:00 Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population 103,99 CHF | -0,17%

2025-10-17 12:37:19 Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML 103,99 CHF | -0,17%

2025-10-16 07:15:00 Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN) 104,17 CHF | +0,47%

2025-09-30 22:15:00 Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU) 103,98 CHF | +3,90%

2025-09-29 14:15:00 Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US 99,24 CHF | +0,92%

2025-09-29 13:44:49 Novartis announces commencement of tender offer to acquire Tourmaline Bio 99,24 CHF | +0,92%

2025-09-26 07:15:00 Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025 98,33 CHF | -0,03%

2025-09-24 08:30:00 New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies 97,83 CHF | +0,32%

2025-09-09 07:00:00 Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD) 102,07 CHF | -0,06%

2025-08-30 17:00:00 Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain

2025-08-18 07:15:00 New Novartis ESC data highlights strength of cardiovascular portfolio 100,18 CHF | +0,88%

2025-08-12 07:15:00 Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure 96,18 CHF | +0,20%

2025-08-11 07:15:00 Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease 95,99 CHF | +2,10%

2025-07-17 07:05:00 Novartis Appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch Retires after 22 Years with the Company 93,15 CHF | -1,92%

2025-07-17 07:00:00 Novartis verzeichnet ein starkes zweites Quartal mit zweistelligem Umsatzwachstum und erhöhter Kerngewinnmarge; Prognose für das operative Kernergebnis im Geschäftsjahr 2025 angehoben 93,15 CHF | -1,92%

2025-07-17 07:00:00 Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance 93,15 CHF | -1,92%

2025-07-08 07:15:00 Novartis receives approval for first malaria medicine for newborn babies and young infants 97,69 CHF | +0,06%

2025-07-03 07:15:00 Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA) 96,89 CHF | -1,65%

2025-06-25 15:13:26 Novartis completes acquisition of Regulus Therapeutics 94,94 CHF | -0,46%

2025-06-25 07:00:00 Novartis announces expiration of Regulus Therapeutics tender offer 94,94 CHF | -0,46%

2025-06-23 07:00:00 Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer 95,08 CHF | +0,11%

2025-06-12 08:00:00 Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH 98,15 CHF | +1,00%

2025-06-02 07:15:00 Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer 95,30 CHF | +1,06%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Novartis

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden